Natera Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
5,470
- Stock Symbol
-
NTRA
- Investments
-
3
- Share Price
-
$322.94
- (As of Thursday Closing)
Natera General Information
Description
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Contact Information
Website
www.natera.comCorporate Office
- 13011 McCallen Pass, Building A
- Suite 100
- Austin, TX 78753
- United States
Corporate Office
- 13011 McCallen Pass, Building A
- Suite 100
- Austin, TX 78753
- United States
Natera Stock Performance
As of 12-Nov-2026, Natera’s stock price is $322.94. Its current market cap is $46.8B with 145M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $322.94 | $319.82 | $181.00 - $437.41 | $46.8B | 145M | 1.71M | -$1.12 |
Natera Financials Summary
As of 30-Sep-2026, Natera has a trailing 12-month revenue of $2.91B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 58,723,213 | 31,102,688 | 20,452,294 | 7,032,124 |
| Revenue | 2,908,875 | 2,306,113 | 1,696,911 | 1,082,571 |
| EBITDA | (182,937) | (266,427) | (191,326) | (422,148) |
| Net Income | (164,714) | (208,160) | (190,426) | (434,801) |
| Total Assets | 2,748,415 | 2,398,344 | 1,660,735 | 1,441,699 |
| Total Debt | 238,844 | 214,377 | 187,118 | 441,993 |
Natera Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Natera Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Natera Comparisons
Industry
Financing
Details
Natera Competitors (12)
One of Natera’s 12 competitors is Invitae, a Formerly VC-backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Invitae | Formerly VC-backed | San Francisco, CA | ||||
| Myriad Genetics | Corporation | Salt Lake City, UT | ||||
| Guardant Health | Formerly VC-backed | Palo Alto, CA | ||||
| Aspira Women's Health | Formerly VC-backed | Austin, TX | ||||
| Gene By Gene | Formerly VC-backed | Houston, TX |
Natera Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Natera Patents
Natera Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026231549-A1 | Improved control strategy for high-throughput sequencing methods | Pending | 28-Apr-2025 | ||
| WO-2026222091-A1 | Neural network-based neoantigen selection | Pending | 16-Apr-2025 | ||
| WO-2026217483-A1 | Methods for predicting and selecting neoantigens | Pending | 07-Apr-2025 | ||
| WO-2026213165-A2 | Methods for cancer detection and monitoring | Pending | 01-Apr-2025 | ||
| WO-2026213165-A3 | Methods for cancer detection and monitoring | Pending | 01-Apr-2025 |
Natera Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Natera Investments & Acquisitions (3)
Natera’s most recent deal was a Merger/Acquisition with Foresight Diagnostics for . The deal was made on 04-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Foresight Diagnostics | 04-Dec-2025 | Merger/Acquisition | Business/Productivity Software | ||
| Invitae (Non-Invasive Prenatal Screening Carrier Screening Business in San Francisco, California) | 22-Jan-2024 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| MyOme | 21-Jun-2022 | Later Stage VC | Other Healthcare Services |
Natera ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
21.56 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Natera Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Foresight Diagnostics | Boulder, CO | 2020 |
Natera FAQs
-
When was Natera founded?
Natera was founded in 2004.
-
Where is Natera headquartered?
Natera is headquartered in Austin, TX.
-
What is the size of Natera?
Natera has 5,470 total employees.
-
What industry is Natera in?
Natera’s primary industry is Laboratory Services (Healthcare).
-
Is Natera a private or public company?
Natera is a Public company.
-
What is Natera’s stock symbol?
The ticker symbol for Natera is NTRA.
-
What is the current stock price of Natera?
As of 12-Nov-2026 the stock price of Natera is $322.94.
-
What is the current market cap of Natera?
The current market capitalization of Natera is $46.8B.
-
What is Natera’s current revenue?
The trailing twelve month revenue for Natera is $2.91B.
-
Who are Natera’s competitors?
Invitae, Myriad Genetics, Guardant Health, Aspira Women's Health, and Gene By Gene are some of the 12 competitors of Natera.
-
What is Natera’s annual earnings per share (EPS)?
Natera’s EPS for 12 months was -$1.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
